Nitric Oxide News and Research

RSS

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.

8 May 2014

Common drug may improve blood flow in muscles of boys with Duchenne muscular dystrophy

A drug typically prescribed for erectile dysfunction or increased pressure in the arteries may help improve blood flow in the muscles of boys with Duchenne muscular dystrophy, according to a study published in the May 7, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.

8 May 2014

New findings show combination of statins and omega-3 fatty acid may potentially reduce cardiovascular risk

New findings from an in vitro study, led by researchers at Brigham and Women's Hospital (BWH), show that the combination of statins and eicosapentaenoic acid (EPA), an omega-3 fatty acid, may potentially reduce cardiovascular risk.

2 May 2014

Study: Ginsenoside Rb1 attenuates neuronal damage following cerebral ischemia

Activated microglia-mediated inflammation promotes neuronal damage under cerebral hypoxic-ischemic conditions, so it is likely that inhibiting hypoxia-induced activation of microglia will alleviate neuronal damage.

7 Apr 2014

Low levels of oxygen, nitric oxide appear to have unfortunate synergy for patients with sickle cell disease

Low levels of both oxygen and the powerful blood vessel dilator nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.

21 Mar 2014

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris.

19 Mar 2014

Peanut consumption offers significant benefits to people with elevated serum lipids and blood pressure

A new study just released in the American Journal of Clinical Nutrition found that different flavors of peanuts – salted, spicy, honey-roasted, or unsalted – result in positive health benefits. The study, "A Randomized Trial on the Effects of Flavorings on the Health Benefits of Daily Peanut Consumption," was conducted at Purdue University and included over 150 men and women who incorporated peanuts into their daily diet for 12 weeks.

10 Mar 2014

Research to identify exact mechanisms behind preterm birth and fetal brain injury

An inflammatory protein that triggers a pregnant mouse's immune response to an infection or other disease appears to cause brain injury in her fetus, but not the premature birth that was long believed to be linked with such neurologic damage in both rodents and humans, new Johns Hopkins-led research suggests.

6 Mar 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014

Cedars-Sinai receives $1M grant to study molecular changes in brain due to air pollutants

Researchers at the Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery at Cedars-Sinai will conduct a study to determine if several potentially toxic compounds that exist in polluted air are capable of entering the brain from the bloodstream and causing brain cancer.

12 Feb 2014

Study on heart attacks identifies potential new treatment target for heart disease

Research led by David Lefer, PhD, Professor and Director of the Cardiovascular Center of Excellence at LSU Health Sciences Center New Orleans School of Medicine, demonstrates for the first time cross-talk between two protective signaling molecules during a heart attack.

11 Feb 2014

Vitamin D deficiency may lead to stiffening of blood vessels

UV-B radiation in sunlight is the most important factor for the production of vitamin D, and that is why many people suffer from low levels of vitamin D during the winter months.

20 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

Increased activities of ClC-3 chloride channel may be involved in hippocampal neuronal apoptosis

Over-production of nitric oxide and ion disturbance are involved in neuronal apoptosis around the ischemic area following ischemic brain injury. Prof. Quanzhong Chang and team from Zhuhai Campus of Zunyi Medical College in China established a rat model of hippocampal neuronal apoptosis by using 3-morpholinosyndnomine (SIN-1), a nitric oxide donor.

6 Jan 2014

Melatonin plays major role in pain transmission

Accumulating research indicates that melatonin has a major role in pain transmission and has an ultra-sensitizing effect. Dr. Fang Huang and colleagues from Sun Yat-sen University in China for the first time located the distribution of melatonin receptor 1 in the caudal spinal trigeminal nucleus.

31 Dec 2013

Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, announced today that its investor group and employee shareholders have reached a definitive agreement to sell the Commercial Business to Madison Dearborn Partners in a transaction valued at approximately $1.6 billion.

26 Dec 2013

Madison Dearborn Partners signs definitive agreement to acquire Ikaria

Madison Dearborn Partners announced today that it has signed a definitive agreement under which it will acquire a majority ownership position in Ikaria, Inc., a leading provider of proprietary and innovative therapies for the critical care units in hospitals.

25 Dec 2013